Company / R&D Expense
Inhibikase Therapeutics, Inc. R&D Expense History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$13.6M
FY2024
5-year range
$893.8K / $13.6M
FY2021-FY2024
Trend
+13.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 3 consecutive years, from $893,802 in FY2021 to $14M in FY2024.
Based on SEC 10-K filings.
$14M in FY2024 with a 3-year CAGR of +147.9%.
Improved from $11M to $14M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +147.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Inhibikase Therapeutics, Inc.'s r&d expense has grown for 3 consecutive years.
- 3-year CAGR of +147.9%, indicating consistent growth.
- In FY2024, r&d expense increased 13.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $13.6M | +13.2% |
| FY2023 | $12.0M | +6.0% |
| FY2022 | $11.4M | +1170.9% |
| FY2021 | $893.8K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026